Additionally, FOXP2 was recognized as an oncogene in several lymphomas including multiple myeloma, and as a tumor suppressor in gastric cancer [49] and hepatocellular carcinoma (HCC) [50] since Lai et al. [51] first demonstrated that FOXP2 is critically involved in a severe language and speech disorder in 2001. This evidence concerns the gene FOXP2 and plasma cell myeloma.